Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Lentivirus Stories

2010-09-30 19:48:02

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons. However, concerns associated with the potential risk of generating...

2010-01-08 15:54:54

Tag-team Approach Breaks the Size Barrier for Gene Therapy Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system. The team has brought together the herpes virus and a molecule known as Sleeping Beauty to improve a technology known as gene therapy, which aims to manipulate genes to correct for molecular flaws that cause disease. The work, detailed in a paper published online in Gene Therapy, has allowed scientists at the...

2009-12-09 09:17:00

GAITHERSBURG, Md,, Dec. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France). The Hepatitis C...

25ca52b95818e665aa0f575ffb4017de
2009-11-06 07:18:17

These findings appear in the November 6, 2009 issue of the journal Science, which is published by AAAS, the nonprofit science society. In a pilot study of two patients monitored for two years, an international team of researchers slowed the onset of the debilitating brain disease X-linked adrenoleukodystrophy (ALD) using a lentiviral vector to introduce a therapeutic gene into patient's blood cells. Although studies with larger cohorts of patients are needed, these results suggest that...

2009-05-19 08:56:17

UCSF scientists have created a method of quickly identifying large numbers of the genetic material known as short hairpin RNA "” also called shRNA "“ that turns genes on and off. The method, which the research team has used to create a library of 22,000 of these "on-off" switches for roughly 600 human genes, provides a tool for scientists throughout the world, with ultimate impacts on the study of the genetic basis of diseases ranging from HIV to high cholesterol, Parkinson's...

2009-04-06 09:41:00

New RNA therapy reversed hemophilia in mice GAITHERSBURG, Md., April 6 /PRNewswire/ -- VIRxSYS Corporation announced today the publication of a new research article, "Trans-splicing into Highly Abundant Albumin Transcripts for Production of Therapeutic Proteins In Vivo," in the journal Molecular Therapy. The study describes a novel RNA therapy technique in which an RNA molecule that is inserted into the albumin gene "hijacks" the albumin, causing it to produce the newly added gene's...

2009-03-05 07:30:00

GERMANTOWN, Md., March 5 /PRNewswire/ -- GeneCopoeia announces the launch of a suite of miRNA functional analysis reagents and tools. They include 1) miExpress(TM) vector based precursor miRNA expression clones; 2) miTarget(TM) miRNA target sequence (3' UTR) expression clones; and 3) All-in-One(TM) miRNA RT-qPCR system. Constructed in a lentiviral vector system, miExpress(TM) precursor miRNA expression clone collections cover all known miRNAs for human (750), mouse (450), and rat (270)....

2009-03-03 07:15:00

ST. LOUIS, March 3 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the global release of the MISSION(R) LentiPlex(TM) Pooled Human and Murine shRNA Libraries (http://www.sigma-aldrich.com/lentiplex). Using the shRNA collections of The RNAi Consortium (TRC), the MISSION LentiPlex Pooled shRNA Libraries enable rapid, genome-wide RNAi screening at the bench-top level in a convenient and powerful, pooled lentiviral format. As a member of both TRC-1 and TRC-2...

2009-02-04 09:17:00

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A. Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene...

2005-08-22 14:14:14

A virus that typically infects insects could help with the development of gene therapy treatment for Hemophilia A, a condition in which even a bump on the knee can cause serious internal bleeding in people. Researchers at the University of Iowa Roy J. and Lucille A. Carver College of Medicine improved a vector -- a vehicle that delivers gene therapy to cells -- in two ways to create a sustained, partial correction to bleeding problems in mice engineered to have Hemophilia A, which is also...